Pritchard on possible new Fez/4050 announcement End of year target (which management always take longer than they estimate) for a new Fezagrapras indication. How many years cash do they have? Does the market believe anything this company does?
In terms of the pipeline and where we're going, again, we're working very hard on this right now. As you know, the ongoing MAD study is progressing. We're almost at the end of that. By the time, we analyze the remainder of that data look at the additional preclinical work that we're looking at, at the moment with fezagepras. We would hope that we are in a position to provide further granularity on both where we're going with the fezagepras program, and indeed the timing and outlook for both the GPR84 and OXER1 programs in a similar sort of time frame. So, certainly before the end of this calendar year.